The Lustgarten Foundation for Pancreatic Cancer Research Company Profile

15:59 EST 19th December 2014 | BioPortfolio

Founded in 1998 by Cablevision executive Marc Lustgarten, with Cablevision chairman Charles Dolan and CEO James Dolan, The Lustgarten Foundation is the nation's largest private, non-profit supporter of pancreatic cancer research, providing more than $20 million to date. The Foundation provides patient information and manages a national public awareness campaign. To learn more and to see Dr. Pausch's PSA, visit www.lustgarten.org.


News Articles [6698 Associated News Articles listed on BioPortfolio]

Seven new projects announced by the UK's Pancreatic Cancer Research Fund

(Pancreatic Cancer Research Fund) The UK research charity, the Pancreatic Cancer Research Fund, has invested £1.2 million into seven ambitious new research projects. The announcement coincides with W...

Factors that may contribute to pancreatic cancer: New insight

New research provides a better understanding of pancreatic cancer, and may help identify individuals at increased risk. Pancreatic cancer is a stealthy cancer that is usually detected at very late sta...

Pancreatic cancer survival rates at standstill for four decades

Long-term survival from pancreatic cancer has failed to improve in 40 years – with the outlook remaining the lowest of the 21 most common cancers, according to new figures published by Cancer Resear...

Cancer Research UK and Astellas join forces on pancreatic cancer treatment

Japanese drug major Astellas Pharma is joining forces with Cancer Research UK and its commercial arm, Cancer Research Technology (CRT), to find new drug targets in the fight against cancer, with an in...

Pancreatic survival rates at standstill for 4 decades

(Cancer Research UK) Long-term survival from pancreatic cancer has failed to improve in 40 years -- with the outlook remaining the lowest of the 21 most common cancers, according to new figures publis...

New trick for 'old' drug brings hope for pancreatic cancer patients

Cancer Research UK scientists have found a new use for an old drug by showing that it shrinks a particular type of pancreatic cancer tumour and stops it spreading, according to research published in G...

Members of the European Parliament launch a call to action to fight against pancreatic cancer on eve of first World Pancreatic Cancer Awareness Day

A call-to-action raising the critical need for focus on pancreatic cancer was announced today in the European Parliament. This call-to-action, titled 'Giving a voice to pancreatic cancer', aims to en...

Cancer Research U.K., Cancer Research Technology ink agreement with Astellas

Cancer Research U.K. and its commercial arm, Cancer Research Technology (CRT), have joined with Astellas Pharma to conduct a two-year research program in the U.K. to find new drug targets in the fig...

PubMed Articles [8869 Associated PubMed Articles listed on BioPortfolio]

A Decrease in miR-150 Regulates the Malignancy of Pancreatic Cancer by Targeting c-Myb and MUC4.

Pancreatic cancer is an aggressive cancer with high mortality. Conventional treatments have little impact on its progression. Limited research investigating the role of oncogene miR-150 specifically i...

Role of pancreatic stellate cells in chemoresistance in pancreatic cancer.

Pancreatic cancer is highly chemoresistant. A major contributing factor is the characteristic extensive stromal or fibrotic reaction, which comprises up to 90% of the tumor volume. Over the last decad...

Association between Allergies and Risk of Pancreatic Cancer.

Less than 10% of pancreatic cancer cases survive 5 years, yet its etiology is not well understood. Studies suggest allergies are associated with reduced pancreatic cancer risk. Our study collected add...

Activation of the Wnt pathway through Wnt2 promotes metastasis in pancreatic cancer.

Wnt signaling pathway plays an important role in physiological and pathological process, including in the occurrence and development of tumor. The purpose of this study is to determine whether Wnt2 an...

Oxidative stress and cytokines in the pathogenesis of pancreatic cancer.

Pancreatic cancer is one of the most aggressive, drug-resistant and lethal types of cancer with poor prognosis. Various factors including reactive oxygen species, cytokines, growth factors, and extrac...

Clinical Trials [3735 Associated Clinical Trials listed on BioPortfolio]

Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

The purpose of this research study is to try to define the highest doses of temsirolimus and gemcitabine that can be used safely in combination to treat advanced pancreatic cancer. Gemcita...

Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.

This no treatment research study is being done to find a safe and an appropriate dose of antibody (protein) against tumor cells to best target the cancer in people with pancreatic cancer. ...

BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study

The purpose of this study is to test the safety, activity and best doses of FOLFOX-A which consists of the standard chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and abraxane. E...

Local Invasion of Pancreatic Cancer

Pancreatic cancer often spreads through local invasion into local structures, including fat, blood vessels, nerves, and nearby organs (stomach, duodenum, spleen, bile duct). Local microsco...

Capecitabine and Radiation Therapy in Advanced Pancreatic Cancer

Pancreatic cancer has traditionally been treated with chemotherapy and radiation therapy with limited results. Preliminary studies of parts of this program in patients with advanced panc...

Companies [2350 Associated Companies listed on BioPortfolio]

The Lustgarten Foundation for Pancreatic Cancer Research

Founded in 1998 by Cablevision executive Marc Lustgarten, with Cablevision chairman Charles Dolan and CEO James Dolan, The Lustgarten Foundation is the nation's largest private, non-profit support...

The Lustgarten Foundation

The Lustgarten Foundation, based in Bethpage, New York, is America's largest private foundation dedicated solely to funding pancreatic cancer research. Founded in 1998, the Foundation provides critica...

Sky Foundation, Inc.

After being diagnosed with pancreatic cancer in 2007 and responding well to treatment, Kasselman established Sky Foundation to fund research for the Sky Foundation Pancreatic Cancer Research Fund at t...

Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is the only national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organizat...

Pancreatic Cancer Action

About Pancreatic Cancer Action: 5 year survival rates for pancreatic cancer have not changed in over 40 years and it is our mission to change this by way of increased awareness of pancreatic cancer...

More Information about "The Lustgarten Foundation for Pancreatic Cancer Research" on BioPortfolio

We have published hundreds of The Lustgarten Foundation for Pancreatic Cancer Research news stories on BioPortfolio along with dozens of The Lustgarten Foundation for Pancreatic Cancer Research Clinical Trials and PubMed Articles about The Lustgarten Foundation for Pancreatic Cancer Research for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Lustgarten Foundation for Pancreatic Cancer Research Companies in our database. You can also find out about relevant The Lustgarten Foundation for Pancreatic Cancer Research Drugs and Medications on this site too.

Search BioPortfolio:
Loading
Advertisement
Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record